An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Trial Profile

An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs ALXN 1007 (Primary)
  • Indications Antiphospholipid syndrome
  • Focus Adverse reactions; Proof of concept
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 14 Jun 2017 Status changed from completed to discontinued.
    • 29 Mar 2017 This trial has been discontinued in UK (End date:2015-08-31) as per European Clinical Trials Database record.
    • 02 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top